GLOBAL DERMATOLOGY ESSENTIALS: Psoriasis

Inquiry 特集コンテンツプレゼンテーション講演者情報

Introducing the Event on Psoriasis at the end of October. The session will be chaired by Dr. Maria-Angeliki GKINI (UK / Greece)

We are pleased to announce an upcoming event focused on psoriasis, a chronic inflammatory dermatosis that affects millions of people worldwide. This event aims to bring together experts and researchers in the field of dermatology to discuss the latest advancements and research on psoriasis.

Psoriasis is a challenging condition that significantly impacts patients’ quality of life. Over the years, traditional treatments have evolved to target specific inflammatory loops involved in psoriasis, such as anti-TNFalpha, anti-IL-17, IL-23, and small molecules like Aprémilast. The development of small molecules has opened new possibilities for effective and convenient treatment options.

During this event, renowned speakers and experts will present their insights on various aspects of psoriasis. The presentations will cover a wide range of topics, including general pustular psoriasis, current guidelines, and future treatments. Additionally, the event will focus on the role of teledermatology in the diagnosis and therapy of psoriasis, as well as the cardiovascular comorbidities associated with the condition.

Prof. Ahmed Samaouel CHEHAD MD from Algeria will provide an introduction to psoriasis and the importance of small molecules in its treatment.

Prof. Adam REICH MD, PhD from Poland will discuss the current guidelines and future treatments for general pustular psoriasis, shedding light on the promising role of anti-Interleukin-36 (IL-36) therapy. Dr. Maria-Angeliki GKINI from Switzerland will share valuable insights into the use of teledermatology in the diagnosis and therapy of psoriasis, highlighting its benefits in improving access to care.

Prof. Tiago TORRES MD, PhD from Portugal will delve into the relationship between psoriasis and cardiovascular comorbidities, exploring the potential of biological therapy in managing both skin symptoms and cardiovascular risk factors.

These presentations will provide attendees with a comprehensive understanding of psoriasis and its treatment options, focusing on the role of small molecules and other innovative approaches. The event will offer a unique opportunity for researchers, dermatologists, and healthcare professionals to exchange knowledge, discuss advancements, and foster collaborations in the field of psoriasis.

Please mark your calendars for the end of October to join us at this informative and enlightening event. Stay tuned for further updates on the event schedule and registration details.

特集コンテンツ

ビデオを視聴するには、登録し、ログインする必要があります

Introduction to the series

ビデオを視聴するには、登録し、ログインする必要があります

Introduction

教授 Adam Reich MD. PhD (Poland)

Prof. Adam Reich is the full time Professor and the Head of the Department of Dermatology, as well as the Director of the Institute of Medical Sciences, University of Rzeszow, Rzeszw, Poland. He is also the Secretary General of the Polish Dermatological Society and Vice-Chair of the Youth Forum of the Polish Dermatological Society.

ビデオを視聴するには、登録し、ログインする必要があります

General pustular psoriasis: current guidelines and future treatments

Based on current understanding, the diagnosis of general pustular psoriasis (GPP) requires observation of primary, sterile, macroscopically visible pustules on non-acral skin, and it must be a relapsing disease, with symptoms lasting more than three months or recurring episodes. Anti-Interleukin-36 (IL-36) therapy shows promise in treating GPP, as research suggests that deficiency of the antagonist of the IL-36 receptor is linked to the disease’s pathogenesis. However, more research is needed to fully understand the role of IL-36 in GPP and its potential as a therapeutic target. Until then, the management of GPP should follow current guidelines, including systemic treatment and supportive care to control symptoms and prevent complications.

ビデオを視聴するには、登録し、ログインする必要があります

Q&A

医者 Maria-Angeliki Gkini MD. Msc. PhD (イギリス)

Dr. Maria-Angeliki GKINI is a Consultant Dermatologist at 401 General Army Hospital in Athens, Greece, and a Locum Consultant Dermatologist at Barts Health NHS Trust in London. With expertise in psoriasis and inflammatory skin diseases, she has contributed to numerous research studies, spoken at international conferences, and received awards from prestigious institutions, including the European Academy of Dermatology and Venereology. Dr. Gkini's interests also extend to artificial intelligence in dermatology and multidisciplinary approaches to skin conditions.

ビデオを視聴するには、登録し、ログインする必要があります

Artificial Intelligence and Psoriatric disease

Dr Gkini has a special interest in inflammatory skin diseases, hair diseases, and psychodermatology. In her presentation, will discuss the application of artificial intelligence in the management of psoriatic disease. The topic starts by defining Artificial intelligence which is a term that has gained popularity in recent times, but there is currently a lack of a standard definition. The umbrella term of artificial intelligence also includes machine learning and deep learning. Deep learning refers to neural networks that have multiplayers of neurons with adjustable weights, inspired by biology. Then the presenter moves to psoriasis.

ビデオを視聴するには、登録し、ログインする必要があります

Introduction

教授 Chander Grover MD (インド)

Dr. Chander Grover is a renowned dermatologist and professor at the University College of Medical Sciences. With over 12 years of experience, her expertise lies in nail disorders, dermatoscopy, pediatric dermatology, and medical education. Dr. Grover has authored numerous publications and books, earning recognition through awards such as the BM Ambady Oration and VN Sehgal Award for her exceptional work in the field of dermatology and nail disorders. She is also the Founder Secretary of the Nail Society of India and actively contributes to various academic and research organizations.

ビデオを視聴するには、登録し、ログインする必要があります

Nail Psoriasis

Nail psoriasis is a challenging aspect of psoriasis that affects not only the nails but also the overall quality of life for individuals dealing with this condition. In this presentation, Professor Grover will delve into the clinical nuances, diagnostic approaches, and management strategies for nail psoriasis. Her depth of knowledge promises to offer us valuable insights into this complex facet of psoriatic disease.

ビデオを視聴するには、登録し、ログインする必要があります

Q&A

ビデオを視聴するには、登録し、ログインする必要があります

Introduction

教授 Tiago Torres Md. PhD (Portugal)

Tiago Torres is Professor of Dermatology at the Instituto de Cincias Biomdicas Abel Salazar, University of Porto. He received his medical degree from the Faculdade de Medicina, University of Porto, completed a residency program in Dermatology and Venereology at Centro Hospitalar Universitrio do Porto (CHUP) and finished his PhD thesis in 2014 studying the role of psoriasis- associated systemic inflammation in atherosclerosis.

ビデオを視聴するには、登録し、ログインする必要があります

Cardiovascular comorbidities and Psoriasis

Psoriasis patients commonly experience cardiometabolic comorbidities, including obesity, hypertension, dyslipidemia, diabetes, and metabolic syndrome, which increase their risk of cardiovascular disease. Psoriasis-associated inflammation contributes to atherosclerosis, exacerbated by the comorbidities. Obesity is a central risk factor in psoriasis due to its role in inflammation and adipose tissue dysfunction. Epicardial adipose tissue volume increases in psoriasis, further contributing to cardiovascular risk. However, biological therapy targeting inflammatory cytokines and adipokines involved in psoriasis and cardiovascular disease has shown promise in reducing inflammation, psoriasis symptoms, and cardiovascular risk factors. Integrating biological therapy in psoriasis management can improve skin symptoms and reduce cardiovascular risk.

ビデオを視聴するには、登録し、ログインする必要があります

Q&A

ビデオを視聴するには、登録し、ログインする必要があります

Introduction

教授 Ahmed Samaouel Chehad MD

ビデオを視聴するには、登録し、ログインする必要があります

Interest in small molecules in psoriasis / Intérêt des Small molécules dans le psoriasis

Psoriasis, a chronic inflammatory dermatosis that affects 125 million people worldwide. The condition severely impacts patients' quality of life, and prompt treatment is necessary to limit cumulative burdens. Traditional treatments have evolved to target specific inflammatory loops that play a role in psoriasis, including anti-TNFalpha, anti-IL-17, IL-23, and small molecules like Aprémilast. Patients' preferences for treatments prioritize subcutaneous per os options that avoid severe side effects and improve daily activity. Aprémilast, the only innovative per os treatment authorized for psoriasis, is a small molecule that crosses the intestinal barrier. Clinical studies demonstrated Aprémilast's superiority over placebos for moderate to severe psoriasis, with significant improvements in nail and scalp psoriasis.

ビデオを視聴するには、登録し、ログインする必要があります